Fordyce Marshall 4

What Happened

• Marshall Fordyce, President, CEO and Director of Vera Therapeutics (VERA), was granted a total of 206,300 equity awards on February 4, 2026: 68,800 shares reported as acquired and 137,500 shares reported as a derivative award. All awards show an acquisition price of $0.00 (typical for compensation grants), so the reported cash value at grant is $0 on the Form 4. The 137,500 derivative awards are restricted stock units (RSUs) that convert into shares subject to vesting.

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026.
• Reported items: 68,800 shares (acquired) and 137,500 derivative shares (RSUs); total = 206,300.
• Price: $0.00 per share (award/grant — not an open-market purchase).
• Shares owned after transaction: not explicitly stated in the filing. The filing does note prior holdings and arrangements: 623 shares purchased via the 2021 ESPP (F2); a transfer of 99,081 shares to The Fordyce Revocable Trust on Nov 19, 2025 (F3); and outstanding options with a 1/48 monthly vesting schedule beginning March 4, 2026 (F4).
• Relevant footnote on vesting: The RSUs (per footnote F1) vest one-fourth on each of Feb 20, 2027, 2028, 2029 and 2030, subject to continued service.
• Filing timeliness: Form filed two days after the transaction date; filing does not indicate a late reporting designation.

Context

• RSUs are derivative awards that convert into actual shares only as they vest; they are compensation, not an immediate market purchase or sale. Grants and transfers (including gifts to trusts) typically reflect compensation and estate/holding-structure actions rather than an explicit insider market signal.